<ul><li>Innoventric, a leader in transcatheter tricuspid regurgitation (TR) treatment, has secured $28.5 million in a Series B funding round.</li><li>The funding will be used to advance clinical trials and expand regulatory approvals in the US and Europe.</li><li>Innoventric's flagship device, utilizing a unique cross-caval approach, aims to restore function to the tricuspid valve without directly interacting with the heart.</li><li>The device offers broad patient applicability, innovative anchoring technique, and a streamlined procedure, revolutionizing tricuspid valve treatment.</li></ul>

Innoventric Secures $28.5M to Expand Transcatheter Tricuspid Valve Treatment

Discover more